# BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct07469774/  
OnCo record `nct07469774` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in advanced solid tumours, run by Biocity Biopharmaceutics Co., Ltd., now recruiting.

## Summary

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07469774 by Biocity Biopharmaceutics Co., Ltd., with 111 participants planned, started 2026-03-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: BC3195 and Pembrolizumab/KEYTRUDA®.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07469774
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- Sponsor: Biocity Biopharmaceutics Co., Ltd.
- Enrolled: 111

## Sources

- ClinicalTrials.gov NCT07469774: https://clinicaltrials.gov/study/NCT07469774

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct07469774.json